Locations
4 min read
Compounded Semaglutide and Tirzepatide in Minnesota: How to Access GLP-1 Treatment Online
Minnesota has seen a notable rise in adult obesity rates in recent years. According to the Trust for America's Health State of Obesity 2025 report, which analyzes 2024 BRFSS data, 32.3% of Minnesota adults have obesity — a meaningful increase from prior years and approaching the national average of 34.3%.1 With a population of more than 5.7 million, that represents hundreds of thousands of Minnesotans who may benefit from evidence-based weight management treatment.
Minnesota has one of the lowest uninsured rates in the country. According to the U.S. Census Bureau's 2024 American Community Survey, 4.2% of Minnesota residents are uninsured — among the lowest of any state and well below the national average of 7.9%.2 Minnesota expanded Medicaid (Medical Assistance) under the Affordable Care Act and has a long history of broad public health coverage. However, even with relatively high insurance rates, Medicaid and most private insurance plans in Minnesota do not cover compounded GLP-1 medications. For Minnesota residents in Minneapolis, St. Paul, Rochester, Duluth, Stillwater, Ames, and communities across the state, online telehealth programs like Fig offer a transparent, affordable path to GLP-1 treatment.
Can I Get Compounded GLP-1 Medication in Minnesota?
Yes. Fig is a telehealth platform that serves all 50 states, including Minnesota. The process is entirely online — no in-person visit, no waiting room, and no travel required.
You complete a free online health assessment, a licensed medical provider reviews your information, and if treatment is determined to be clinically appropriate, a prescription is issued and medication is shipped directly to your Minnesota address at no additional shipping cost.
What Does Fig Offer Minnesota Residents?
Fig offers access to compounded semaglutide and compounded tirzepatide when prescribed by a licensed provider as clinically appropriate. Both medications are prepared by state-licensed, FDA-registered 503A compounding pharmacies in the United States.
Fig's pricing is all-inclusive with zero membership fees, zero consultation fees, and zero shipping charges added at checkout.
Medication Monthly Plan 3-Month Plan 6-Month Plan Compounded Semaglutide $179/mo $160/mo $145/mo Compounded Tirzepatide $279/mo $249/mo $233/mo
Many competing telehealth platforms charge a mandatory monthly membership fee of $100 to $149 on top of medication costs. Fig charges zero membership fees. The price shown is the total price paid.
How the Fig Process Works in Minnesota
Complete Fig's free online health assessment from anywhere in Minnesota, covering your medical history, current medications, and weight management goals.
A licensed medical provider reviews your information and determines whether treatment is clinically appropriate.
If a prescription is issued, pricing is shown transparently before any payment is required.
Medication and supplies are shipped discreetly to your Minnesota address at no additional shipping cost.
Ongoing support is included throughout your treatment experience.
The process is fully asynchronous. There are no scheduled video appointments, and you can complete the intake on your own schedule, whether you are in the Twin Cities metro area, Rochester, Duluth, or a rural community in Greater Minnesota.
Does Insurance Cover GLP-1 Medication in Minnesota?
Most insurance plans in Minnesota, including Medical Assistance (Medicaid) and MinnesotaCare, do not cover compounded GLP-1 medications. Coverage for brand-name GLP-1s like Ozempic and Wegovy exists in some commercial plans but typically requires prior authorization, a documented diagnosis of obesity or type 2 diabetes, and often documented failure of prior weight loss interventions.
Fig does not require insurance to begin. The eligibility process is open to any Minnesota resident who meets the clinical criteria.
FSA and HSA funds may be eligible for use toward Fig's plans. Compounded GLP-1 medications prescribed for a diagnosed medical condition generally qualify as a medical expense under IRS guidelines. Check with your plan administrator to confirm.
Frequently Asked Questions
Does Fig ship to all parts of Minnesota, including rural areas?
Yes. Fig ships to all Minnesota addresses, including Minneapolis, St. Paul, Rochester, Duluth, Bloomington, and rural communities throughout Greater Minnesota.
Do I need a Minnesota-licensed doctor to use Fig?
No. Fig's network of licensed providers can evaluate and prescribe for Minnesota residents through the telehealth platform.
Is compounded semaglutide the same as Ozempic or Wegovy?
No. Compounded semaglutide is not the same as, nor a substitute for, FDA-approved semaglutide products such as Ozempic or Wegovy. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality.
Can I use my FSA or HSA card to pay for Fig?
In most cases, yes. Because Fig's pricing is all-inclusive with no separate membership fee, the full cost is typically eligible as a qualified medical expense. Confirm with your FSA or HSA administrator.
Can I cancel anytime?
Yes. Fig offers month-to-month options and patients can cancel anytime, subject to any active orders already in processing.
Getting Started
Minnesota residents looking for transparent, affordable access to GLP-1 weight management can start Fig's free eligibility assessment at startfig.com.
Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality. Fig does not guarantee weight loss results. Individual outcomes vary. Treatment is only prescribed when a licensed provider determines it is clinically appropriate.
Footnotes
Trust for America's Health. State of Obesity 2025: Better Policies for a Healthier America. 2024 BRFSS data. https://www.tfah.org/report-details/state-of-obesity-report-2025/ ↩
U.S. Census Bureau. Health Insurance Coverage by State: 2023 and 2024. American Community Survey 1-Year Estimates, 2024. https://www2.census.gov/library/publications/2025/demo/acsbr-024.pdf ↩